Shares of Hemostemix Inc. (CVE:HEM – Get Free Report) were down 19.4% during trading on Thursday . The stock traded as low as C$0.14 and last traded at C$0.15. Approximately 519,694 shares traded hands during trading, a decline of 1% from the average daily volume of 526,987 shares. The stock had previously closed at C$0.18.
Hemostemix Stock Down 19.4 %
The firm’s 50-day moving average price is C$0.20 and its 200-day moving average price is C$0.12. The company has a market cap of C$21.13 million, a price-to-earnings ratio of -4.23 and a beta of 0.20. The company has a debt-to-equity ratio of -55.07, a current ratio of 0.04 and a quick ratio of 0.48.
About Hemostemix
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Featured Articles
- Five stocks we like better than Hemostemix
- What is the Euro STOXX 50 Index?
- SoundHound AI Stock at a Crossroads—Is a Bottom in Sight?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Hershey’s Sweet Comeback: Why Investors Are Taking Notice
- How to buy stock: A step-by-step guide for beginners
- 3 Reasons Occidental Petroleum Will Gush Higher in 2025
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
